Strategic electrochemical oxidation of vinblastin sulfate (an anticancer drug) via PVP-functionalized strontium oxide nanoparticles
Cancer is a primary cause of death worldwide, and considerably impacts mortality rates in low- and middle-income countries. The rise in chemotherapeutic patients and toxicity of cytotoxic agents highlight the need for reliable analytical methods to detect these compounds. The current study presents...
Saved in:
Published in: | RSC advances Vol. 14; no. 43; pp. 31387 - 31397 |
---|---|
Main Authors: | , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
Royal Society of Chemistry
01-10-2024
The Royal Society of Chemistry |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Cancer is a primary cause of death worldwide, and considerably impacts mortality rates in low- and middle-income countries. The rise in chemotherapeutic patients and toxicity of cytotoxic agents highlight the need for reliable analytical methods to detect these compounds. The current study presents a simple and straightforward method for producing polyvinylpyrrolidone functionalized strontium oxide nanoparticles (PVP-SrO NPs). The synthesized PVP-SrO NPs were applied as a sensitive sensor to detect vinblastin sulfate (VNB) (an anticancer drug). The synthesized PVP-SrO NPs were characterized using different characterization techniques. Fourier transform infrared spectroscopy (FTIR) confirms the functionality of synthesized PVP-SrO NPs. The sharp intense peaks of X-ray diffraction spectroscopy (XRD) confirm the crystalline nature of NPs, scanning electron microscopy (SEM) confirm the nanobeads like morphology, and energy dispersive spectroscopy (EDS) reveals the presence of Sr and O at 68.3% and 23% respectively. The electrochemical impedance spectroscopy and cyclic voltammetry studies revealed that the PVP-SrO/GCE is more conductive than bare GCE with an
value of 960.4 Ω compared to 2440 Ω. The sensor exhibited a wide linear dynamic range for VNB (0.05 to 60 μM) with low LOD 0.005 μM, and LOD 0.017 μM. The proposed sensor was successfully used for monitoring VNB in human blood serum samples with a satisfactory percent recovery from 96% to 103%. The fabricated sensor exhibits better performance than the reported sensors in terms of processing, simplicity, cost-effectiveness, energy consumption, and enhanced efficacy in a very short time. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 2046-2069 2046-2069 |
DOI: | 10.1039/d4ra05493h |